JP2022527788A5 - - Google Patents
Info
- Publication number
- JP2022527788A5 JP2022527788A5 JP2021557927A JP2021557927A JP2022527788A5 JP 2022527788 A5 JP2022527788 A5 JP 2022527788A5 JP 2021557927 A JP2021557927 A JP 2021557927A JP 2021557927 A JP2021557927 A JP 2021557927A JP 2022527788 A5 JP2022527788 A5 JP 2022527788A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- exon
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025038928A JP2025090740A (ja) | 2019-03-29 | 2025-03-12 | Ｅｇｆｒまたはｈｅｒ２エクソン２０挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962826843P | 2019-03-29 | 2019-03-29 | |
| US62/826,843 | 2019-03-29 | ||
| PCT/US2020/025228 WO2020205521A1 (en) | 2019-03-29 | 2020-03-27 | Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025038928A Division JP2025090740A (ja) | 2019-03-29 | 2025-03-12 | Ｅｇｆｒまたはｈｅｒ２エクソン２０挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022527788A JP2022527788A (ja) | 2022-06-06 |
| JP2022527788A5 true JP2022527788A5 (https=) | 2023-04-04 |
| JP7650814B2 JP7650814B2 (ja) | 2025-03-25 |
Family
ID=72666976
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021557927A Active JP7650814B2 (ja) | 2019-03-29 | 2020-03-27 | Ｅｇｆｒまたはｈｅｒ２エクソン２０挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 |
| JP2025038928A Pending JP2025090740A (ja) | 2019-03-29 | 2025-03-12 | Ｅｇｆｒまたはｈｅｒ２エクソン２０挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025038928A Pending JP2025090740A (ja) | 2019-03-29 | 2025-03-12 | Ｅｇｆｒまたはｈｅｒ２エクソン２０挿入を有するがん細胞に対する抗腫瘍活性を有する化合物 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20220143023A1 (https=) |
| EP (1) | EP3946293A4 (https=) |
| JP (2) | JP7650814B2 (https=) |
| KR (1) | KR20210149103A (https=) |
| CN (1) | CN113939284A (https=) |
| AU (1) | AU2020254499A1 (https=) |
| BR (1) | BR112021019489A2 (https=) |
| CA (1) | CA3131864A1 (https=) |
| IL (1) | IL286742A (https=) |
| MX (1) | MX2021011948A (https=) |
| PH (1) | PH12021552395A1 (https=) |
| SG (1) | SG11202110669WA (https=) |
| WO (1) | WO2020205521A1 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110129434A (zh) * | 2018-02-08 | 2019-08-16 | 埃提斯生物技术（上海）有限公司 | 胆汁中生物标志物在诊断恶性肿瘤中的应用 |
| BR112021016149A2 (pt) | 2019-02-26 | 2021-10-13 | Janssen Biotech, Inc. | Terapias de combinação e estratificação de pacientes com anticorpos biespecíficos anti-egfr/c-met |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
| EP3956035A4 (en) * | 2019-04-17 | 2023-01-25 | Board of Regents, The University of Texas System | ANTI-CANCER LINKS WITH TYROSINE KINASE RESISTANT EGFR MUTATIONS |
| US11850248B2 (en) | 2019-05-14 | 2023-12-26 | Yuhan Corporation | Therapies with 3rd generation EGFR tyrosine kinase inhibitors |
| US11879013B2 (en) | 2019-05-14 | 2024-01-23 | Janssen Biotech, Inc. | Combination therapies with bispecific anti-EGFR/c-Met antibodies and third generation EGFR tyrosine kinase inhibitors |
| JP7783182B2 (ja) | 2020-02-12 | 2025-12-09 | ヤンセン バイオテツク，インコーポレーテツド | ｃ－ＭＥＴエクソン１４スキッピング変異を有する患者の治療 |
| PY21113397A (es) * | 2020-12-29 | 2022-10-12 | Spectrum Pharmaceuticals Inc | Tratamiento para tumores sólidos malignos |
| WO2022206929A1 (zh) * | 2021-04-01 | 2022-10-06 | 上海医药集团股份有限公司 | 一种化合物在制备靶向ErbB2突变体的抑制药物中的应用 |
| WO2023015149A1 (en) * | 2021-08-02 | 2023-02-09 | Spectrum Pharmaceuticals, Inc. | Treatment of non-small cell lung cancer with poziotinib |
| KR20230063731A (ko) | 2021-11-02 | 2023-05-09 | 주식회사 엘지에너지솔루션 | 전해액의 분할 주입을 포함하는 이차전지의 제조방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10308658B2 (en) * | 2015-10-19 | 2019-06-04 | Sunshine Lake Pharma Co., Ltd. | Salt of EGFR inhibitor, crystalline form and uses thereof |
| KR102771603B1 (ko) * | 2016-11-17 | 2025-02-24 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | Egfr 또는 her2 엑손 20 돌연변이를 갖는 암 세포에 대한 항종양 활성을 갖는 화합물 |
| EP3687542A1 (en) * | 2017-09-27 | 2020-08-05 | AI Therapeutics, Inc. | Therapeutic methods relating to hsp90 inhibitors |
| WO2019178239A1 (en) * | 2018-03-13 | 2019-09-19 | Board Of Regents, The University Of Texas System | Methods for treatment of cancers with egfr activating mutations |
| AU2019243738B2 (en) * | 2018-03-27 | 2024-05-30 | Board Of Regents, The University Of Texas System | Compounds with anti-tumor activity against cancer cells bearing HER2 exon 19 mutations |
| MX2021011948A (es) * | 2019-03-29 | 2022-01-04 | Univ Texas | Compuestos con actividad antitumoral contra células cancerígenas que llevan inserciones de exon 20 effr o her2. |
-
2020
- 2020-03-27 MX MX2021011948A patent/MX2021011948A/es unknown
- 2020-03-27 US US17/599,969 patent/US20220143023A1/en not_active Abandoned
- 2020-03-27 AU AU2020254499A patent/AU2020254499A1/en not_active Abandoned
- 2020-03-27 CN CN202080038791.0A patent/CN113939284A/zh active Pending
- 2020-03-27 WO PCT/US2020/025228 patent/WO2020205521A1/en not_active Ceased
- 2020-03-27 PH PH1/2021/552395A patent/PH12021552395A1/en unknown
- 2020-03-27 CA CA3131864A patent/CA3131864A1/en active Pending
- 2020-03-27 KR KR1020217035240A patent/KR20210149103A/ko active Pending
- 2020-03-27 JP JP2021557927A patent/JP7650814B2/ja active Active
- 2020-03-27 BR BR112021019489A patent/BR112021019489A2/pt not_active Application Discontinuation
- 2020-03-27 EP EP20783802.0A patent/EP3946293A4/en active Pending
- 2020-03-27 SG SG11202110669WA patent/SG11202110669WA/en unknown
-
2021
- 2021-09-27 IL IL286742A patent/IL286742A/en unknown
-
2025
- 2025-03-12 JP JP2025038928A patent/JP2025090740A/ja active Pending
- 2025-04-01 US US19/097,461 patent/US20250312348A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022527788A5 (https=) | ||
| JP2020502059A5 (https=) | ||
| JP2022529016A5 (https=) | ||
| JP2022529945A5 (https=) | ||
| ES2208766T3 (es) | Procedimiento de deteccion de mutaciones ki-ras y equipo para llevarlo a cabo. | |
| EP2348111A9 (en) | PROBES FOR DETECTING MUTATIONS OF kRas GENE, LIQUICHIP AND DETECTION METHODS THEREOF | |
| EP2580322B1 (en) | A mek 1 mutation conferring resistance to raf and mek inhibitors | |
| CN104781423A (zh) | 对胃癌进行分类的分组方法 | |
| JP2021517894A5 (https=) | ||
| US20180298447A1 (en) | Methods for assessing the treatment response of cancer patients and for treating cancer patients by analysing cpg methylation | |
| CN106148498A (zh) | Kras基因突变检测试剂盒及其应用 | |
| Cavic et al. | Pharmacogenetics in cancer therapy-8 years of experience at the Institute for Oncology and Radiology of Serbia | |
| JP2022527499A5 (https=) | ||
| JP2021519306A5 (https=) | ||
| EP3150717A1 (en) | Pik3ca gene mutation detection kit | |
| RU2020134932A (ru) | Соединения с противоопухолевой активностью против раковых клеток, несущих мутации в экзоне 19her2 | |
| EP3473250B1 (en) | Ddr2 mutations as targetable features of melanoma or basal cell carcinoma | |
| US20220305008A1 (en) | Treatment of cancer having gnaq or gna11 genetic mutations with protein kinase c inhibitors | |
| JP2022515128A5 (https=) | ||
| CN106399514A (zh) | Nras基因突变检测试剂盒 | |
| JP7334194B2 (ja) | Ｔｐ５３突然変異状態及び高頻度突然変異状態に基づくがん治療法 | |
| CN114807366A (zh) | 一种人肿瘤特异性braf突变检测方法 | |
| CN107841793A (zh) | 肺癌多基因突变文库的构建方法 | |
| Nemtsova et al. | Molecular classifications of gastric cancer and their clinical potential | |
| Barranco | Key role for microbiota in gut–bone crosstalk |